Neoplastic interactions of hepatitis C virus with telomerase.
Neoplastic interactions of hepatitis C virus with telomerase.
批准号:
10047694
负责人:
WARREN N SCHMIDT
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-04-01 至 2021-09-30
关键词:
AchievementAntineoplastic AgentsAntiviral AgentsAntiviral TherapyBehaviorBindingBiopsy SpecimenCancer DetectionCancer EtiologyCellsChronic Hepatitis CCirrhosisComplexCore ProteinDNADataDevelopmentDrug TargetingEnzymesEpidemicEventFoundationsFutureGenetic TranscriptionGoalsGrantHealthHepatitis CHepatitis C TherapyHepatitis C virusHepatocarcinogenesisHepatocyteHoloenzymesHumanIn VitroIncidenceInfectionInjuryLaboratoriesLeadLengthLiverLiver diseasesMaintenanceMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of liverMusNeoplasmsNuclearOncogenic VirusesPatientsPeptide HydrolasesPrimary carcinoma of the liver cellsProteinsRNA-Directed DNA PolymeraseSignal TransductionStructureSystemTelomeraseTranscriptional ActivationTranscriptional RegulationVeteransViralViral Core ProteinsVirusWNT Signaling PathwayWorkbeta catenincancer cellcancer therapycellular targetingexperimental studyhelicasehumanized mousein vivolifetime riskmouse modelneoplasticpreventpromoterrepair functionrepairedtelomeretumor progressionvirtual
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Chronic hepatitis C infection (HCV) is a worldwide health problem that can lead to cirrhosis, end
stage liver disease, and hepatocellular carcinoma (HCC). Because of the HCV epidemic, the
incidence of HCC is rising at an alarming rate and US veterans with cirrhosis have 5-8% lifetime
risk of developing hepatocellular carcinoma (HCC). New, highly effective, antiviral therapies for
HCV have recently become available, but these have had little impact on development of HCC
and it is virtually unknown how the virus causes cancer. Our group has been studying the
effects of HCV on the host cellular enzyme telomerase, which is a reverse transcriptase (RT)
that repairs short chromosomal DNA 3' “telomeric” ends in dividing cells. Adequate telomere
lengths must be maintained to avoid chromosomal injury and to support continuous cellular
replication. Consequently, telomerase is induced or upregulated in the majority of malignant
cells and has proven to be a valuable cellular target enzyme for cancer detection and anticancer
therapy.
Our laboratory has recently shown that HCV induces telomerase early after infection and we
hypothesize that this behavior contributes to the virus' oncogenicity. Induction of telomerase is
likely facilitated in part through the actions of HCV proteins core, NS5A and NS3-4A in the host
hepatocyte. We have also demonstrated that HCV core and NS5A proteins transcriptionally
activate TERT promoter and that NS3-4A, the viral protease-helicase complex, binds
specifically to TERT and stimulates telomerase catalytic activity. Our data are the first to show
that HCV can induce TERT expression as well as catalytically activate host telomerase. The
overlying hypothesis of this application is that HCV reactivates telomerase through initial
interactions with the Wnt/β-catenin signaling system which then drives TERT promoter to open
transcription. This is likely accomplished by core and NS5A which have been shown to stabilize
activated Wnt/β-catenin signaling complexes. We also hypothesize that NS3-4A, a
multifunctional protease-helicase, increases telomerase catalytic activity by optimizing the
enzyme's type II processivity. By increasing telomerase processivity, NS3-4A thus promotes
efficiency of telomere repair and facilitates neoplastic progression. Collectively, the actions of
the virus upregulate chromosomal maintenance and repair mechanisms and promote
hepatocarcinogenesis. The long term goals of our work are two-fold: we wish to determine the
mechanisms of how the virus induces telomerase expression and increases telomerase
catalytic activity. Achievement of both of these goals will lead to the identification of cellular
events that are undoubtedly important for HCC development and ultimately treatment. This
approach is highly relevant for understanding how HCV promotes liver cancer and the data will
lay a firm foundation for eventual drug targeting of telomerase or the viral helicase with
anticancer agents.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.2147/pgpm.s52629
发表时间:
2014
期刊:
Pharmacogenomics and personalized medicine
影响因子:
1.9
作者:
[Kayali Z, Schmidt WN]
通讯作者:
Schmidt WN
DOI:
10.1371/journal.pone.0166853
发表时间:
2017
期刊:
PloS one
影响因子:
3.7
作者:
[Zhu Z, Tran H, Mathahs MM, Moninger TO, Schmidt WN]
通讯作者:
Schmidt WN
DOI:
10.3389/fphar.2012.00129
发表时间:
2012
期刊:
Frontiers in pharmacology
影响因子:
5.6
作者:
[Schmidt WN, Mathahs MM, Zhu Z]
通讯作者:
Zhu Z
DOI:
10.1002/prp2.882
发表时间:
2021-12
期刊:
Pharmacology research & perspectives
影响因子:
2.6
作者:
[Zhu Z, Tran H, Mathahs MM, Fink BD, Albert JA, Moninger TO, Meier JL, Li M, Schmidt WN]
通讯作者:
Schmidt WN
Anti HCV Protease Activities of Metalloporphyrins
-
批准号:8803233
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:WARREN N SCHMIDT
-
依托单位:
Anti HCV Protease Activities of Metalloporphyrins
-
批准号:8666517
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:WARREN N SCHMIDT
-
依托单位:
Heme Oxygenase-1 Inhibition of Hepatitis C Replication
-
批准号:8262609
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:WARREN N SCHMIDT
-
依托单位:
Heme Oxygenase-1 Inhibition of Hepatitis C Replication
-
批准号:8195610
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:WARREN N SCHMIDT
-
依托单位:
Anti HCV Protease Activities of Metalloporphyrins
-
批准号:8441039
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:WARREN N SCHMIDT
-
依托单位:
Heme Oxygenase-1 Inhibition of Hepatitis C Replication
-
批准号:7686494
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:WARREN N SCHMIDT
-
依托单位:
Heme Oxygenase-1 Inhibition of Hepatitis C Replication
-
批准号:7787492
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:WARREN N SCHMIDT
-
依托单位:
Heme Oxygenase-1 and Hepatitis C
-
批准号:7051949
-
项目类别:
-
资助金额:$15.38万
-
财政年份:2005
-
负责人:WARREN N SCHMIDT
-
依托单位:
Heme Oxygenase-1 and Hepatitis C
-
批准号:6921206
-
项目类别:
-
资助金额:$18.82万
-
财政年份:2005
-
负责人:WARREN N SCHMIDT
-
依托单位:
THALIDOMIDE IN PATIENTS WITH ACUTE ALCOHOLIC HEPATITIS
-
批准号:7201331
-
项目类别:
-
资助金额:$0.19万
-
财政年份:2005
-
负责人:WARREN N SCHMIDT
-
依托单位:
THALIDOMIDE IN PATIENTS WITH ACUTE ALCOHOLIC HEPATITIS
-
批准号:7040813
-
项目类别:
-
资助金额:$0.94万
-
财政年份:2004
-
负责人:WARREN N SCHMIDT
-
依托单位:
ALCOHOL EFFECTS ON LIVER DISEASE IN HCV AND HIV COINFECT
-
批准号:6292036
-
项目类别:
-
资助金额:$17.17万
-
财政年份:2000
-
负责人:WARREN N SCHMIDT
-
依托单位:
ALCOHOL EFFECTS ON LIVER DISEASE IN HCV AND HIV COINFECT
-
批准号:6532398
-
项目类别:
-
资助金额:$17.26万
-
财政年份:2000
-
负责人:WARREN N SCHMIDT
-
依托单位:
ALCOHOL EFFECTS ON LIVER DISEASE IN HCV AND HIV COINFECT
-
批准号:6371856
-
项目类别:
-
资助金额:$17.26万
-
财政年份:2000
-
负责人:WARREN N SCHMIDT
-
依托单位:
QUANTITATION OF HEPATITIS C VIRUS IN PERIPHERAL BLOOD
-
批准号:6138089
-
项目类别:
-
资助金额:$7.35万
-
财政年份:1999
-
负责人:WARREN N SCHMIDT
-
依托单位:
QUANTITATION OF HEPATITIS C VIRUS IN PERIPHERAL BLOOD
-
批准号:2736877
-
项目类别:
-
资助金额:$7.02万
-
财政年份:1999
-
负责人:WARREN N SCHMIDT
-
依托单位:
QUANTITATION OF HEPATITIS C VIRUS IN PERIPHERAL BLOOD
-
批准号:6342532
-
项目类别:
-
资助金额:$7.35万
-
财政年份:1999
-
负责人:WARREN N SCHMIDT
-
依托单位:
HEPATITIS C AND CRYOGLOBULINEMIA
-
批准号:2002730
-
项目类别:
-
资助金额:$8.96万
-
财政年份:1997
-
负责人:WARREN N SCHMIDT
-
依托单位:
HEPATITIS C AND CRYOGLOBULINEMIA
-
批准号:2886057
-
项目类别:
-
资助金额:$8.96万
-
财政年份:1997
-
负责人:WARREN N SCHMIDT
-
依托单位:
HEPATITIS C AND CRYOGLOBULINEMIA
-
批准号:2671456
-
项目类别:
-
资助金额:$8.96万
-
财政年份:1997
-
负责人:WARREN N SCHMIDT
-
依托单位:
海外基金